Molecular studies of the Oka varicella vaccine

References

• Mori I, Nishiyama Y. Herpes simplex virus and varicella zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev. Med. Virol.15, 393–406 (2005).
   PubMed Web of Science ®Google Scholar
• McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpesvirus genomics and evolution. Virus. Res.117, 90–104 (2006).
   PubMed Web of Science ®Google Scholar
• Quinlivan M, Breuer J. Molecular and therapeutic aspects of varicella zoster virus infection. Expert Rev. Mol. Med.7, 1–24 (2005).
   Google Scholar
• Arvin AM, Moffat JF, Redman R. Varicella zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv. Virus Res.46, 263–309 (1996).
   PubMed Web of Science ®Google Scholar
• Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM. Tropism of varicella zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J. Virol.76, 11425–11433 (2002).
   PubMed Web of Science ®Google Scholar
• Ito Y, Kimura H, Hara S et al. Investigation of varicella zoster virus DNA in lymphocyte subpopulations by quantitative PCR assay. Microbiol. Immunol.45, 267–269 (2001).
   PubMed Web of Science ®Google Scholar
• Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ. Abbarent intracellular localization of varicella zoster virus regulatory proteins during latency. Proc. Natl Acad. Sci. USA95, 7080–7085 (1998).
   PubMed Web of Science ®Google Scholar
• Mahalingam R, Wellish M, Cohrs R et al. Expression of protein encoded by varicella zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl Acad. Sci. USA93, 2122–2124 (1996).
   PubMed Web of Science ®Google Scholar
• Cohrs RJ, Gilden DH, Kinchington PR, Grinfeld E, Kennedy PG. Varicella zoster virus gene 66 transcription and translation in latently infected human ganglia. J. Virol.77, 6660–6665 (2003).
   PubMed Web of Science ®Google Scholar
• Quinlivan ML, Ayres KL, Kelly PJ et al. Persistence of varicella zoster virus viraemia in patients with herpes zoster. J. Clin. Virol.50, 130–135 (2011).
   PubMed Web of Science ®Google Scholar
• Weinberg A, Lazar AA, Zerbe GO et al. Influence of age and nature of primary infection on varicella zoster virus-specific cell-mediated immune responses. J. Infect. Dis.201, 1024–1030 (2010).
   PubMed Web of Science ®Google Scholar
• Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J. Clin. Immunol.7, 174–178 (1987).
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A et al. A predictive model of varicella zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin. Infect. Dis.32, 1414–1422 (2001).
   PubMed Web of Science ®Google Scholar
• Herr W, Plachter B. Cytomegalovirus and varicella zoster virus vaccines in hematopoietic stem cell transplantation. Expert Rev. Vaccines8(8), 999–1021 (2009).
   PubMed Web of Science ®Google Scholar
• Zambelli A, Montagna D, Da Prada GA et al. Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res.22, 3701–3708 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet2, 1288–1290 (1974).
   PubMed Web of Science ®Google Scholar
• Singhvi R, Markusen JF, Ky B, Horvath BJ, Aunins JG. Assessment of virus infection in cultured cells using metabolic monitoring. Cytotechnology22, 79–85 (1986).
   Google Scholar
• D’Hondt E, Berge E, Colinet G, Duchene M, Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad. Med. J.61(Suppl. 4), 53–56 (1985).
   PubMedGoogle Scholar
• Galea SA, Sweet A, Beninger P et al. The safety profile of varicella vaccine: a 10-year review. J. Infect. Dis.197(Suppl. 2), S165–S169 (2008).
   PubMed Web of Science ®Google Scholar
• Bonanni P, Breuer J, Gershon A et al. Varicella vaccination in Europe – taking the practical approach. BMC Med.7, 26 (2009).
   PubMed Web of Science ®Google Scholar
• Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine28, 5878–5882 (2010).
   PubMed Web of Science ®Google Scholar
• Clements DA, Moreira SP, Coplan PM, Bland CL, Walter EB. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr. Infect. Dis. J.18, 1047–1050 (1999).
   PubMed Web of Science ®Google Scholar
• Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics122, 744–751 (2008).
   PubMed Web of Science ®Google Scholar
• Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J. Infect. Dis.174(Suppl. 3), S324–S329 (1996).
   PubMed Web of Science ®Google Scholar
• White CJ, Kuter BJ, Hildebrand CS et al. Varicella vaccine (Varivax) in healthy children and adolescents results from clinical trials, 1987 to 1989. Pediatrics87, 604–610 (1991).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. Development of a live attenuated varicella vaccine. Biken J.18, 25–33 (1975).
   PubMedGoogle Scholar
• Kuter BJ, Ngai A, Patterson CM et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck varicella vaccine study group. Vaccine13, 967–972 (1995).
   PubMed Web of Science ®Google Scholar
• Wutzler P, Knuf M, Liese J. Varicella: efficacy of two-dose vaccination in childhood. Dtsch. Arztebl. Int.105, 567–572 (2008).
   PubMed Web of Science ®Google Scholar
• Chaves SS, Gargiullo P, Zhang JX et al. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. Med.356, 1121–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Kuter B, Matthews H, Shinefield H et al. Study group for Varivax. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J.23, 132–137 (2004).
   PubMed Web of Science ®Google Scholar
• Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Garson A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin. Infect. Dis.34, 774–779 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine18, 2375–2380 (2000).
   PubMed Web of Science ®Google Scholar
• Sharrar RG, LaRussa P, Galea SA et al. The postmarketing safety profile of varicella vaccine. Vaccine19, 916–923 (2000).
   PubMed Web of Science ®Google Scholar
• Bernstein HH, Rothstein EP, Watson BM et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics92, 833–837 (1993).
   PubMed Web of Science ®Google Scholar
• Huang WC, Huang LM, Chang IS, Tsai FY, Chang LY. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine29, 2756–2760 (2011).
   PubMed Web of Science ®Google Scholar
• Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J. Infect. Dis.203, 316–323 (2011).
   PubMed Web of Science ®Google Scholar
• Chouliaras G, Spoulou V, Quinlivan M, Breuer J, Theodoridou M. Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics125, 969–972 (2009).
   Google Scholar
• Lyer S, Mittal MK, Hodinka RL. Herpes zoster and meningitis resulting from reactivation of varicella vaccine virus in an immunocompetent child. Ann. Emerg. Med.53, 792–795 (2009).
   PubMed Web of Science ®Google Scholar
• Chaves SS, Haber P, Walton K et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J. Infect. Dis.197(Suppl. 2), S170–S177 (2008).
   PubMed Web of Science ®Google Scholar
• Levin MJ, DeBiasi RL, Bostik V, Schmid DS. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella zoster virus vaccine. J. Infect. Dis.198, 1444–1447 (2008).
   PubMed Web of Science ®Google Scholar
• Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella zoster virus, in an immunosuppressed child. J. Infect. Dis.188, 954–959 (2003).
   PubMed Web of Science ®Google Scholar
• Gan L, Wang M, Yang S, Gershon AA, Chen JJ. Transmission of varicella vaccine virus to a non-family member in China. Vaccine29(11), 2015–2017 (2010).
   PubMed Web of Science ®Google Scholar
• LaRussa P, Steinberg S, Meurice F, Gershon A. Transission of vaccine strain varicella zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J. Infect. Dis.176, 1072–1075 (1997).
   PubMed Web of Science ®Google Scholar
• Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J. Pediatr.148, 842–844 (2006).
   PubMed Web of Science ®Google Scholar
• Weibel RE, Neff BJ, Kuter BJ et al. Live attenuated varicella virus vaccine. Efficacy trail in healthy children. N. Engl. J. Med.310, 1409–1415 (1984).
   PubMed Web of Science ®Google Scholar
• Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Paediatrics78, 748–756 (1986).
   PubMed Web of Science ®Google Scholar
• Gershon AA, Steinberg SP, Gelb L et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA252, 355–362 (1984).
   PubMed Web of Science ®Google Scholar
• Breuer J. Oka vaccine for varicella zoster virus. Herpes4, 62–67 (1997).
   Google Scholar
• Weinmann S, Chun C, Riedlinger K et al. Herpes zoster in the varicella vaccine era. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vacouver, Canada, 21–24 October 2010.
   Google Scholar
• Civen R, Chaves SS, Jumaan A et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr. Infect. Dis. J.28, 954–959 (2009).
   PubMed Web of Science ®Google Scholar
• Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. N. Engl. J. Med.318, 543–548 (1988).
   PubMed Web of Science ®Google Scholar
• Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N . Engl. J. Med.325, 1545–1550 (1991).
   PubMed Web of Science ®Google Scholar
• Gomi Y, Imagawa T, Takahashi M, Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J. Med. Virol.61, 497–503 (2000).
   PubMed Web of Science ®Google Scholar
• Argaw T, Cohen JI, Klutch M et al. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella zoster isolates. J. Infect. Dis.181, 1153–1157 (2000).
   PubMed Web of Science ®Google Scholar
• Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J. Virol.76, 11447–11459 (2002).
   PubMed Web of Science ®Google Scholar
• Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. Complete DNA sequences of two oka strain varicella zoster virus genomes. J. Virol.82, 11023–11044 (2008).
   PubMed Web of Science ®Google Scholar
• Schmid DS. Varicella zoster virus vaccine. molecular genetics. Curr. Top. Microbiol. Immunol.342, 323–340 (2010).
   PubMed Web of Science ®Google Scholar
• Quinlivan ML, Gershon AA, Al Bassam MM et al. Natural selection for rash-forming genotypes of the varicella zoster vaccine virus detected within immunized human hosts. Proc. Natl Acad. Sci. USA104, 208–212 (2007).
   PubMed Web of Science ®Google Scholar
• Kanda RK, Quinlivan ML, Gershon AA, Nichols RA, Breuer J. Population diversity in batches of the varicella Oka vaccine. Vaccine29(17), 3293–3298 (2011).
   Web of Science ®Google Scholar
• Kreth HW, Hoeger PH. Members of the VZV-AD study group. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur. J. Pediatr.165, 677–683 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi M. 25 years’ experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr. Drugs3, 285–292 (2001).
   PubMed Web of Science ®Google Scholar
• Lau YL, Vessey SJ, Chan IS et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine20, 2942–2949 (2002).
   PubMed Web of Science ®Google Scholar
• Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine28, 686–691 (2010).
   PubMed Web of Science ®Google Scholar
• Seward JF, Marin M, Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J. Infect. Dis.197(Suppl. 2), S82–S89 (2008).
   PubMed Web of Science ®Google Scholar
• Kreth HW, Lee BW, Kosuwon P et al. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix). BioDrugs22, 387–402 (2008).
   PubMed Web of Science ®Google Scholar
• Bayer O, Heininger U, Heiligensetzer C, von Kries R. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine25, 6655–6660 (2007).
   PubMed Web of Science ®Google Scholar
• Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM. Varicella zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J. Virol.84, 9240–9253 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen JI. Infection of cells with varicella zoster virus down-regulates surface expression of class I major histocompatibility complex antigens. J. Infect. Dis.177, 1390–1393 (1998).
   PubMed Web of Science ®Google Scholar
• Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J. Virol.75, 4878–4888 (2001).
   PubMed Web of Science ®Google Scholar
• Black AP, Jones L, Malavige GN, Ogg GS. Immune evasion during varicella zoster virus infection of keratinocytes. Clin. Exp. Dermatol.34, 941–944 (2009).
   PubMed Web of Science ®Google Scholar
• Gutzeit C, Raftery MJ, Peiser M et al. Identification of an important immunological difference between virulent varicella zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction. J. Immunol.185, 488–497 (2010).
   PubMed Web of Science ®Google Scholar
• Morrow G, Slobedman B, Cunningham AL, Abendroth A. Varicella zoster virus productively infects mature dendritic cells and alters their immune function. J. Virol.77, 4950–4959 (2003).
   PubMed Web of Science ®Google Scholar
• Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, Arvin AM. Modulation of major histocompatability class II protein expression by varicella zoster virus. J. Virol.74, 1900–1907 (2000).
   PubMed Web of Science ®Google Scholar
• Koropchak CM, Graham G, Palmer J et al. Investigation of varicela-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J. Infect. Dis.163, 1016–1022 (1991).
   PubMed Web of Science ®Google Scholar
• Mainka C, Fuss B, Geiger H, Hofelmayr H, Wolff MH. Characterization of viraemia at different stages of varicella zoster virus infection. J. Med. Virol.56, 91–98 (1998).
   PubMed Web of Science ®Google Scholar
• Hawrami K, Breuer J. Development of a flurogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. J. Virological Methods79, 33–40 (1999).
   PubMed Web of Science ®Google Scholar
• Sawyer MH, Wu NY, Chamberlin CJ et al. Detection of varicella zoster virus DNA in the orphopharynx and blood of patients with varicella. J. Infect. Dis.166, 885–888 (1992).
   PubMed Web of Science ®Google Scholar
• Ozaki T, Kajita Y, Asano Y, Aono T, Yamanishi K. Detection of varicella zoster virus DNA in blood of children with varicella. J. Med. Virol.44, 263–265 (1994).
   PubMed Web of Science ®Google Scholar
• Gomi Y, Ozaki T, Nishimura N. DNA sequence analysis of varicella zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine26, 5627–5632 (2008).
   PubMed Web of Science ®Google Scholar
• Moffat JF, Stein MD, Kaneshima H, Arvin AM. Tropism of varicella zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J. Virol.69, 5236–5242 (1995).
   PubMed Web of Science ®Google Scholar
• Soong W, Schultz JC, Patera AC, Sommer MH, Cohen JI. Infection of human T lymphocytes with varicella zoster virus: an analysis with viral mutants and clinical isolates. J. Virol.74, 1864–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Pathogenetic tropism of varicella zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts. J. Infect. Dis.188, 1875–1877 (2003).
   PubMed Web of Science ®Google Scholar
• Chen JJ, Zhu Z, Gershon AA, Gershon MD. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell119, 915–926 (2004).
   PubMed Web of Science ®Google Scholar
• Mahalingam R, Smith D, Wellish M et al. Simian varicella virus DNA in dorsal root ganglia. Proc. Natl Acad. Sci. USA88, 2750–2752 (1991).
   PubMed Web of Science ®Google Scholar
• Arvin A. Varicella zoster virus. In: Virology. Fields BN, Knipe DM (Eds). Lippincott-Raven Publishers, Philadelphia, PA, USA 2547–4587 (1998).
   Google Scholar
• Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM. Varicella zoster virus infection of human dorsal root ganglia in vivo. Proc. Natl Acad. Sci. USA102, 6490–6495 (2005).
   PubMed Web of Science ®Google Scholar
• Gershon AA, Gershon MD. Perspectives on vaccines against varicella zoster virus infections. Curr. Top. Microbiol. Immunol.342, 359–372 (2010).
   PubMed Web of Science ®Google Scholar
• Schmidt M, Kress M, Heinemann S, Fickenscher H. Varicella zoster virus isolates, but not the vaccine strain Oka, induce sensitivity to α-1 and β-1 adrenergic stimulation of sensory neurons in culture. J. Med. Virol.70(Suppl. 1), S82–S89 (2003).
   Google Scholar
• Kress M, Fickenscher H. Infection by human varicella zoster virus confers norepinephrine sensitivity to sensory neurons from rat dorsal root ganglia. FASEB J.15, 1037–1043 (2001).
   PubMed Web of Science ®Google Scholar
• Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. Attenuation of the vaccine Oka strain of varicella zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol.72, 965–974 (1998).
   PubMed Web of Science ®Google Scholar
• Jones JO, Arvin AM. Microarray analysis of host cell gene transcription in response to varicella zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J. Virol.77, 1268–1280 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Selariu A, Warden C et al. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog.6(7), e1000971 (2010).
   PubMed Web of Science ®Google Scholar
• Che X, Reichelt M, Sommer MH, Rajamani J, Zerboni L, Arvin AM. Functions of the ORF9-to-ORF12 gene cluster in varicella zoster virus replication and in the pathogenesis of skin infection. J. Virol.82, 5825–5834 (2008).
   PubMed Web of Science ®Google Scholar
• Sato B, Ito H, Hinchliffe S, Sommer MH, Zerboni L, Arvin AM. Mutational analysis of open reading frames 62 and 71, encoding varicella zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J. Virol.77, 5607–5620 (2003).
   PubMed Web of Science ®Google Scholar
• Moriuchi H, Moriuchi M, Cohen JI. Proteins and cis-acting elements associated with transactivation of the varicella zoster virus (VZV) immediate-early gene 62 promoter by VZV open reading frame 10 protein. J. Virol.69, 4693–4701 (1995).
   PubMed Web of Science ®Google Scholar
• Kinchington PR, Hougland JK, Arvin AM, Ruyechan WT, Hay J. The varicella zoster virus immediate-early protein IE62 is a major component of virus particles. J. Virol.66, 359–366 (1992).
   PubMed Web of Science ®Google Scholar
• Moriuchi H, Moriuchi M, Straus SE, Cohen JI. Varicella zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology200, 297–300 (1994).
   PubMed Web of Science ®Google Scholar
• Gomi Y, Imagawa T, Takahashi M, Yamanishi K. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental virus. Arch. Virol.17, 49–56 (2001).
   Google Scholar
• Perera LP, Mosca JD, Ruyechan WT, Hay J. Regulation of varicella zoster virus gene expression in human T lymphocytes. J. Virol.66, 5298–5304 (1992).
   PubMed Web of Science ®Google Scholar
• Perera LP. The TATA motif specifies the differential activation of minimal promoters by varicella zoster virus immediate-early regulatory protein IE62. J. Biol. Chem.275, 487–496 (2000).
   PubMed Web of Science ®Google Scholar
• Folster JM, Jensen NJ, Ruyechan WT, Inoue N, Schmid DS. Regulation of the expression of the varicella zoster virus open reading frame 66 gene. Virus. Res.155, 334–342 (2011).
   PubMed Web of Science ®Google Scholar
• Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J. Mutational analysis of varicella zoster virus major immediate-early protein IE62. Nucleic Acids Res.23, 1341–1349 (1995).
   PubMed Web of Science ®Google Scholar
• Eisfeld AJ, Turse SE, Jackson SA, Lerner EC, Kinchington PR. Phosphorylation of the varicella zoster virus (VZV) major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein kinase. J. Virol.80, 1710–1723 (2006).
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Jackson W, Grose C, Czechowski D, Hay J, Ruyechan WT. The varicella zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV transactivator. J. Virol.81, 761–774 (2007).
   PubMed Web of Science ®Google Scholar
• Peng H, He H, Hay J, Ruyechan WT. Interaction between the varicella zoster virus IE62 major transactivator and cellular transcription factor Sp1. J. Biol. Chem.278, 38068–38075 (2003).
   PubMed Web of Science ®Google Scholar
• Kinchington PR, Fite K, Turse SE. Nuclear accumulation of IE62, the varicella zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase. J. Virol.74, 2265–2277 (2000).
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Eletsky A, Szyperski T, Hay J, Ruyechan WT. Analysis of the varicella zoster virus IE62 N-terminal acidic transactivating domain and its interaction with the human mediator complex. J. Virol.83, 6300–6305 (2009).
   PubMed Web of Science ®Google Scholar
• Ruyechan WT. Roles of cellular transcription factors in VZV replication. Curr. Top. Microbiol. Immunol.342, 43–65 (2010).
   PubMed Web of Science ®Google Scholar
• Kenyon TK, Grose C. VZV ORF47 serine protein kinase and its viral substrates. Curr. Top. Microbiol. Immunol.342, 99–111 (2010).
   PubMed Web of Science ®Google Scholar
• Wagenaar TR, Chow VT, Buranathai C, Thawatsupha P, Grose C. The out of Africa model of varicella zoster virus evolution. single nucleotide polymorphisms and private alleles distinguish Asian clades from European/North American clades. Vaccine21, 1072–1081 (2003).
   PubMed Web of Science ®Google Scholar
• Cohrs RJ, Gilden DH, Gomi Y, Yamanishi K, Cohen JI. Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of varicella zoster virus. J. Virol.80, 2076–2082 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch JM, Kenyon TK, Grose C, Hay J, Ruyechan WT. Physical and functional interaction between the varicella zoster virus IE63 and IE62 proteins. Virology302, 71–82 (2002).
   PubMed Web of Science ®Google Scholar
• Grinfeld E, Ross A, Forster T, Ghazal P, Kennedy PG. Genome-wide reduction in transcriptomal profiles of varicella zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays. Virus Genes38, 19–29 (2009).
   PubMed Web of Science ®Google Scholar
• Moffat JF, Zerboni L, Sommer MH et al. The ORF47 and ORF66 putative protein kinases of varicella zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl Acad. Sci. USA95, 11969–11974 (1998).
   PubMed Web of Science ®Google Scholar
• Moffat J, Ito H, Sommer M, Taylor S, Arvin AM. Glycoprotein I of varicella zoster virus is required for viral replication in skin and T cells. J. Virol.76, 8468–8471 (2002).
   PubMed Web of Science ®Google Scholar
• Arvin AM, Oliver S, Reichelt M et al. Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis. Curr. Top. Microbiol. Immunol.342, 129–146 (2010).
   PubMed Web of Science ®Google Scholar
• Mo C, Lee J, Sommer M, Grose C, Arvin AM. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology304, 176–186 (2002).
   PubMed Web of Science ®Google Scholar
• Ling P, Kinchington PR, Ruyechan WT, Hay J. A detailed analysis of transcripts mapping to varicella zoster virus gene 14 (glycoprotein V). Virology184, 625–635 (1991).
   PubMed Web of Science ®Google Scholar
• Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol.6, 401–410 (2004).
   PubMed Web of Science ®Google Scholar
• Stow ND, Davison AJ. Identification of a varicella zoster virus origin of DNA replication and its activation by herpes simplex virus type 1 gene products. J. Gen. Virol.67, 1613–1623 (1986).
   PubMed Web of Science ®Google Scholar
• Nichols RA, Averbeck KT, Poulsen AG et al. Household size is critical to varicella zoster virus transmission in the tropics despite lower viral infectivity. Epidemics3, 12–18 (2011).
   PubMed Web of Science ®Google Scholar
• Zerboni L, Hinchliffe S, Sommer MH et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology332, 337–346 (2005).
   PubMed Web of Science ®Google Scholar
• Intracellular localization of varicella zoster virus ORF39 protein and its functional relationship to glycoprotein K. Virology358, 291–302 (2007).
   PubMed Web of Science ®Google Scholar
• Grose C. Glycoproteins encoded by varicella zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Ann. Rev. Microbiol.44, 59–80 (1990).
   PubMed Web of Science ®Google Scholar
• Grose C, Edwards DP, Weigle KA, Friedrichs WE, McGuire WL. Varicella zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein. Virology132, 138–146 (1984).
   PubMed Web of Science ®Google Scholar
• Maresova L, Pasieka TJ, Grose C. Varicella zoster virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivilant to those from gH and gL coexpression. J. Virol.75, 9483–9492 (2001).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Hall SL. Role of the varicella zoster virus gB cytoplasmic domain in gB transport and viral egress. J. Virol.76, 591–599 (2002).
   PubMed Web of Science ®Google Scholar
• Kjartansdóttir A, Lycke E, Norrby SR. B-cell epitopes of varicella zoster virus glycoprotein II. Arch. Virol.141, 2465–2469 (1996).
   PubMed Web of Science ®Google Scholar
• Oliver SL, Sommer M, Zerboni L, Rajamani J, Grose C, Arvin AM. Mutagenesis of varicella zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. J. Virol.83, 7495–7506 (2009).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Krudwig N, Hall SL. Cytoplasmic domain signal sequences that mediate transport of varicella zoster virus gB from the endoplasmic reticulum to the Golgi. J. Virol.74, 9421–9430 (2000).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Hall SL. VZV gB endocytosis and Golgi localization are mediated by YXXφ motifs in its cytoplasmic domain. Virology285, 42–49 (2001).
   PubMed Web of Science ®Google Scholar
• Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J. Infect. Dis.190, 793–796 (2004).
   PubMed Web of Science ®Google Scholar
• Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J. Infect. Dis.195, 502–510 (2007).
   PubMed Web of Science ®Google Scholar
• Quinlivan MA, Gershon AA, Nichols RA, La Russa P, Steinberg SP, Breuer J. Vaccine Oka varicella zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions. J. Infect. Dis.193, 927–930 (2006).
   PubMed Web of Science ®Google Scholar
• Breuer J, Schmid DS. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. J. Infect. Dis.197(Suppl. 2), S54–S57 (2008).
   PubMedGoogle Scholar
• Sommer MH, Zagha E, Serrano OK et al. Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J. Virol.75, 8224–8239 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res.39(Database issue), D913–D919 (2011).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tamura T, Hiruma M. Analysis of strain variation of R1 repeated structure in varicella zoster virus DNA by polymersae chain reaction. J. Med. Virol.58, 76–78 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tamura T. An analytical method for R5 repeated structure in varicella zoster virus DNA by polymerase chain reaction. J. Virol. Methods80, 213–215 (1999).
   PubMed Web of Science ®Google Scholar
• Sauerbrei A, Eichhorn U, Gawellek S, Egerer R, Schacke M, Wutzler P. Molecular characterisation of varicella zoster virus strains in Germany and differentiation from the Oka vaccine strain. J. Med. Virol.71, 313–319 (2003).
   PubMed Web of Science ®Google Scholar
• Hawrami K, Breuer J. Analysis of United Kingdom wild-type strains of varicella zoster virus: differentiation from the Oka vaccine strain. J. Med. Virol.53, 60–62 (1997).
   PubMed Web of Science ®Google Scholar
• Mori C, Takahara R, Toriyama T, Nagai T, Takahashi M, Yamanishi K. Identification of the Oka strain of the live attenuated varicella vaccine from other clinical isolates by molecular epidemiologic analysis. J. Infect. Dis.178, 35–38 (1998).
   PubMed Web of Science ®Google Scholar
• LaRussa P, Lungu O, Hardy I, Gershon AA, Steinberg SP, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella zoster virus isolates. J. Virol.66, 1016–1020 (1992).
   PubMed Web of Science ®Google Scholar
• LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA. Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr. Infect. Dis. J.19, 1037–1039 (2000).
   PubMed Web of Science ®Google Scholar
• Larussa PS, Gershon AA. Biologic and geographic differences between vaccine and clinical varicella zoster virus isolates. Arch. Virol. Suppl.17, 41–48 (2001).
   Google Scholar
• Loparev VN, McCaustland K, Holloway BP, Krause PR, Takayama M, Schmid DS. Rapid genotyping of varicella zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J. Clin. Microbiol.38, 4315–4319 (2000).
   PubMed Web of Science ®Google Scholar
• Loparev VN, Gonzalez A, Deleon-Carnes M et al. Global identification of three major genotypes of varicella zoster virus: longitudinal clustering and strategies for genotyping. J. Virol.78, 8349–8358 (2004).
   PubMed Web of Science ®Google Scholar
• Quinlivan M, Hawrami K, Barrett-Muir W et al. The molecular epidemiology of varicella zoster virus: evidence for geographic segregation. J. Infect. Dis.186, 888–894 (2002).
   PubMed Web of Science ®Google Scholar
• Takayama M, Takayama N. New method for differentiating wild-type varicella zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF 6-based PCR and restriction fragment length polymorphism analysis. J. Clin. Virol.29, 113–119 (2004).
   PubMed Web of Science ®Google Scholar
• Quinlivan M, Gershon AA, Steinberg SP, Breuer J. An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella zoster virus. J. Med. Virol.75, 174–180 (2005).
   PubMed Web of Science ®Google Scholar
• Lopez AS, Burnett-Hartman A, Nambiar R et al. Transmission of a newly characterized strain of varicella zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J. Infect. Dis.197, 646–653 (2008).
   PubMed Web of Science ®Google Scholar
• Phumiamorn S, Sato H, Kamiyama T, Kurokawa M, Shiraki K. Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine. J. Gen. Virol.84, 287–291 (2003).
   PubMed Web of Science ®Google Scholar
• Shiraki K, Sato H, Yoshida Y. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen. J. Med. Virol.64, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. J. Med. Virol.70(Suppl. 1), S31–S37 (2003).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect.125, 651–669 (2000).
   PubMed Web of Science ®Google Scholar
• Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine20, 2500–2507 (2002).
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The nature of herpes zoster. a long term study and a new hypothesis. Proc. R. Soc. Med.58, 9–20 (1965).
   PubMedGoogle Scholar
• Garnett GP, Grenfell BT. The epidemiology of varicella zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol. Infect.108, 513–528 (1992).
   PubMed Web of Science ®Google Scholar
• Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet360, 678–682 (2002).
   PubMed Web of Science ®Google Scholar
• Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis.173, 450–453 (1996).
   PubMed Web of Science ®Google Scholar
• Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis.52, 332–340 (2011).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of herpes zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Wkly Rep.57(RR-5), 1–29 (2008).
   PubMedGoogle Scholar